IMMvention retained rights to use its technology to potentially pursue other targets, such as Parkinson’s or Alzheimer’s ...

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...

People with sickle cell disease often struggle with memory, focus, learning and problem solving, setting them back in ...

Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, ...

A new study has found older-looking brains in adults with sickle cell disease, helping to explain the cognitive challenges experienced by such individuals. A brain image from a healthy individual ...

Statistics from the district health department indicate that in 2023, suspected cases of sickle cells stood at 1,456 and in ...

Madhya Pradesh has achieved 100 per cent target by screening 90,98,902 persons for the sickle cell disease so far, a ...

Texas Children's Hospital and Baylor College of Medicine are providing medication and other aid to fight sickle cell disease ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

Individuals with sickle cell disease—a chronic illness where misshapen, sticky blood cells clump together, reducing oxygen ...

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...